The biotech spinout will use the cash to fund clinical development and proof-of-concept for its lead candidate targeting influenza by 2018 and 2019.

Atriva Therapeutics, a Germany-based biotech spinout from University of Münster and Justus Liebig University Gießen, has secured the second tranche of a €3m ($3.5m) seed round co-led by German public-private partnership High-Tech Gründerfonds (HTGF).

Investment firm Stichting Participatie Atriva co-led the round, which also included InSynchrony Ventures, the investment arm of contract pharmaceutical research firm InSymbiosis.

HTGF and Stichting Participatie Atriva previously co-led a first tranche of undisclosed size in February 2017, with participation from unnamed private investors.

Founded in…